Immutep Limited American Depositary Shares (IMMP)

About IMMP

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

www.immutep.com/

Fundamentals

1-day range

$0.3774$0.3965

Market cap

$55.21M

P/E (trailing)

—

P/E (forward)

-1.93

EPS (trailing)

$-0.06

Dividend yield

—

Beta

2.65

Avg. volume

563.3K

Dividend pay date

December 28, 2016

Forecasts

1 analyst ratings

Immutep Limited American Depositary Shares Competitors

Chosen by industry and closest market cap.

• IMMP

  Immutep Limited American Depositary Shares

  $0.3848

  ▲ 1.26%
  Market cap $55.21MP/E —
  $0.028$0.47
• RNXT

  RenovoRx Inc. Common Stock

  $1.68

  ▲ 13.18%
  Market cap $51.86MP/E —
  $0.7006$1.68
• SCYX

  SCYNEXIS Inc. Common Stock

  $5.44

  ▼ 1.45%
  Market cap $51.64MP/E —
  $3.53$10.48
• DWTX

  Dogwood Therapeutics Inc. Common Stock

  $2.6

  ▲ 12.07%
  Market cap $58.85MP/E —
  $1.28$9.5
• XLO

  Xilio Therapeutics Inc. Common Stock

  $9

  ▼ 0.22%
  Market cap $60.95MP/E —
  $6.47$12.74
• IBO

  Impact BioMedical Inc. Common Stock

  $0.444

  ▲ 0.68%
  Market cap $48.61MP/E 0.49
  $0.37$0.83
• TCRT

  Alaunos Therapeutics Inc. Common Stock

  $1.56

  ▼ 6.02%
  Market cap $48.60MP/E —
  $1.55$4.59

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

2.63M

Total value held

$907.6K

Institutional holders

27